Characteristics of the study group
| Parameter . | Value . |
|---|---|
| No. patients | 280 |
| Median age, y (range) | 58 (21-85) |
| Male sex, no. (%) | 144 (51) |
| Median duration of disease, mo (range) | 57 (5-275) |
| Splenomegaly, no. (%) | 48 (17) |
| Median hemoglobin, g/L (range) | 120 (77-172) |
| Median WBC, × 109/L (range) | 9.9 (0.9-372) |
| Median platelet count, × 109/L (range) | 309 (28-2000) |
| Prior complete hematologic response with imatinib, no. (%) | 88 (31) |
| Prior therapy, no. (%) | |
| Allogeneic or stem cell transplantation | 22 (8) |
| Hydroxyurea | 233 (83) |
| Cytarabine | 71 (25) |
| Interferon-α, no. (%) | 184 (66) |
| Imatinib resistance, no. (%) | 194 (69) |
| Maximum previous imatinib dose, no. (%) | |
| Less than 600 mg/day | 77 (28) |
| 600 to 800 mg/day | 91 (33) |
| More than 800 mg/day | 111 (40) |
| Chromosomal abnormalities at baseline other than Ph, no. (%) | 72 (26) |
| ABL kinase domain mutations, no. (%) | 77* (42) |
| Parameter . | Value . |
|---|---|
| No. patients | 280 |
| Median age, y (range) | 58 (21-85) |
| Male sex, no. (%) | 144 (51) |
| Median duration of disease, mo (range) | 57 (5-275) |
| Splenomegaly, no. (%) | 48 (17) |
| Median hemoglobin, g/L (range) | 120 (77-172) |
| Median WBC, × 109/L (range) | 9.9 (0.9-372) |
| Median platelet count, × 109/L (range) | 309 (28-2000) |
| Prior complete hematologic response with imatinib, no. (%) | 88 (31) |
| Prior therapy, no. (%) | |
| Allogeneic or stem cell transplantation | 22 (8) |
| Hydroxyurea | 233 (83) |
| Cytarabine | 71 (25) |
| Interferon-α, no. (%) | 184 (66) |
| Imatinib resistance, no. (%) | 194 (69) |
| Maximum previous imatinib dose, no. (%) | |
| Less than 600 mg/day | 77 (28) |
| 600 to 800 mg/day | 91 (33) |
| More than 800 mg/day | 111 (40) |
| Chromosomal abnormalities at baseline other than Ph, no. (%) | 72 (26) |
| ABL kinase domain mutations, no. (%) | 77* (42) |
indicates n = 182.